Schmid John P. 4

What Happened John P. Schmid, a director of First Tracks Biotherapeutics, received 6,030 shares of common stock on June 15, 2026 through the conversion/settlement of derivative awards (reported under transaction code M). The filing shows 6,030 shares acquired at $0.00; a corresponding derivative disposition of 6,030 units at $0.00 reflects the conversion/settlement. This was the vesting/settlement of restricted stock units (RSUs), not an open‑market purchase or sale.

Key Details

• Transaction date: 2026-06-15; Form 4 filed: 2026-06-17 (timely filing).
• Shares received: 6,030 common shares; reported acquisition price: $0.00 (no cash paid).
• Filing shows a matching derivative disposition of 6,030 units (conversion of the derivative into shares).
• Shares owned after the transaction: not specified in the provided filing.
• Footnotes: F1 — each RSU is a contingent right to one share upon settlement for no consideration. F2 — 100% of the RSUs vested on June 15, 2026, subject to continued service.
• No 10b5-1 plan, tax‑withholding sale, or late filing indicated in the provided data.

Context This transaction reflects routine compensation vesting (RSU settlement) rather than an outright purchase or sale. RSU settlements are common executive/director compensation and do not necessarily signal the insider’s market view, though they do increase the insider’s shareholdings when retained.